Published in Science on June 13, 2003
Traditional ethics and new sensitivities. Schizophr Bull (2005) 0.78
European Union research. Ethics group gives qualified nod to placebos. Science (2003) 1.42
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Social contexts influence ethical considerations of research. Am J Bioeth (2011) 4.02
The MacArthur Treatment Competence Study. III: Abilities of patients to consent to psychiatric and medical treatments. Law Hum Behav (1995) 3.57
The dysregulation of human subjects research. JAMA (2007) 3.44
The ethics of using quality improvement methods in health care. Ann Intern Med (2007) 3.25
The therapeutic misconception: problems and solutions. Med Care (2002) 3.05
Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med (2004) 2.97
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Use of leverage to improve adherence to psychiatric treatment in the community. Psychiatr Serv (2005) 2.62
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
Capacity to provide informed consent for participation in schizophrenia and HIV research. Am J Psychiatry (2002) 2.41
The capacity to appoint a proxy and the possibility of concurrent proxy directives. Behav Sci Law (2006) 2.37
Models of consent to return of incidental findings in genomic research. Hastings Cent Rep (2014) 2.25
Mental health training for law enforcement professionals. J Am Acad Psychiatry Law (2005) 2.24
Proxy and surrogate consent in geriatric neuropsychiatric research: update and recommendations. Am J Psychiatry (2004) 2.20
Evaluating psychiatric disability: differences by forensic expertise. J Am Acad Psychiatry Law (2011) 2.04
Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry (2011) 2.02
A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry (2007) 1.96
The evolution of consent forms for research: a quarter century of changes. IRB (2010) 1.92
Consent form readability and educational levels of potential participants in mental health research. Psychiatr Serv (2007) 1.89
The MacArthur Treatment Competence Study. I: Mental illness and competence to consent to treatment. Law Hum Behav (1995) 1.77
Unrealistic optimism in early-phase oncology trials. IRB (2011) 1.75
Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. Arch Gen Psychiatry (2005) 1.75
Attitudes and practices among internists concerning genetic testing. J Genet Couns (2012) 1.75
Glucose-6-phosphate dehydrogenase-derived NADPH fuels superoxide production in the failing heart. J Mol Cell Cardiol (2006) 1.73
Maintaining informed consent validity during lengthy research protocols. IRB (2008) 1.62
Return of secondary genomic findings vs patient autonomy: implications for medical care. JAMA (2013) 1.60
The MacArthur Treatment Competence Study. II: Measures of abilities related to competence to consent to treatment. Law Hum Behav (1995) 1.60
Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry (2005) 1.57
Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry (2007) 1.56
Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology (2006) 1.53
Ethics and statistics in randomized clinical trials. Stat Sci (1991) 1.49
Researchers' views on return of incidental genomic research results: qualitative and quantitative findings. Genet Med (2013) 1.48
The capacity to vote of persons with serious mental illness. Psychiatr Serv (2009) 1.48
Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology (2009) 1.47
Research ethics for mental health science involving ethnic minority children and youths. Am Psychol (2002) 1.45
Respect for persons and informed consent to participate in research. Clin Res (1977) 1.44
Correlates of treatment-related decision-making capacity among middle-aged and older patients with schizophrenia. Arch Gen Psychiatry (2004) 1.43
Preservation of the capacity to appoint a proxy decision maker: implications for dementia research. Arch Gen Psychiatry (2011) 1.41
Questions on conflict of interest. Am J Psychiatry (2010) 1.38
Multimedia consent for research in people with schizophrenia and normal subjects: a randomized controlled trial. Schizophr Bull (2008) 1.37
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull (2006) 1.35
Do clinicians follow a risk-sensitive model of capacity-determination? An experimental video survey. Psychosomatics (2006) 1.33
Twenty-five years of therapeutic misconception. Hastings Cent Rep (2008) 1.32
Investigative bronchoprovocation and bronchoscopy in airway diseases. Am J Respir Crit Care Med (2005) 1.32
Ethical guidelines in pandemic influenza: recommendations of the Ethics Subcommittee of the Advisory Committee of the Director, Centers for Disease Control and Prevention. Disaster Med Public Health Prep (2009) 1.30
Can psychiatry cross the quality chasm? Improving the quality of health care for mental and substance use conditions. Am J Psychiatry (2007) 1.30
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull (2006) 1.30
The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. Am J Psychiatry (2003) 1.29
Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull (2009) 1.27
Assessment of therapeutic misconception in older schizophrenia patients with a brief instrument. Am J Psychiatry (2006) 1.25
At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull (2012) 1.24
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res (2013) 1.16
Competence to consent to research among long-stay inpatients with chronic schizophrenia. Psychiatr Serv (2003) 1.16
Deliberative assessment of surrogate consent in dementia research. Alzheimers Dement (2010) 1.14
A direct comparison of research decision-making capacity: schizophrenia/schizoaffective, medically ill, and non-ill subjects. Schizophr Res (2008) 1.12
Upregulation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase activity increases oxidative stress in failing human heart. J Card Fail (2007) 1.11
Disclosure of information to potential subjects on research recruitment web sites. IRB (2008) 1.11
Another view of therapy for cognition in schizophrenia. Biol Psychiatry (2002) 1.11
Issues for DSM-V: DSM-V should include a conceptual issues work group. Am J Psychiatry (2008) 1.10
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol (2003) 1.10
Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry (2004) 1.09
Genetic testing in psychiatry: a review of attitudes and beliefs. Psychiatry (2011) 1.09
Ought we to require emotional capacity as part of decisional competence? Kennedy Inst Ethics J (1998) 1.08
Building a new consensus: ethical principles and policies for clinical research on HIV/AIDS. IRB (1991) 1.07
Pharmaceutical research involving the homeless. J Med Philos (2002) 1.07
Research ethics. To protect human subjects, review what was done, not proposed. Science (2012) 1.06
Willingness of subjects with thought disorder to participate in research. Schizophr Bull (2005) 1.04
Information disclosure, subject understanding, and informed consent in psychiatric research. Law Hum Behav (1988) 1.03
Decisional capacity of severely depressed patients requiring electroconvulsive therapy. J ECT (2003) 1.03
Drug-free research in schizophrenia: an overview of the controversy. IRB (1996) 1.03
Competence to complete psychiatric advance directives: effects of facilitated decision making. Law Hum Behav (2007) 1.02
White matter alterations in deficit schizophrenia. Neuropsychopharmacology (2008) 1.02
The silent majority: who speaks at IRB meetings? IRB (2012) 1.02
Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res (2012) 1.01
DSM-5 status of psychotic disorders: 1 year prepublication. Schizophr Bull (2012) 1.01
The challenge of informed consent and return of results in translational genomics: empirical analysis and recommendations. J Law Med Ethics (2014) 1.01
IRBs and pharmaceutical company funding of research. IRB (1982) 1.00
Optimistic bias in the perception of personal risk: patterns in schizophrenia. Am J Psychiatry (2005) 1.00
The reporting of monetary compensation in research articles. J Empir Res Hum Res Ethics (2007) 0.98
The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry (2004) 0.98
Assessing competence to complete psychiatric advance directives with the competence assessment tool for psychiatric advance directives. Compr Psychiatry (2004) 0.97
Prevalence and correlates of adequate performance on a measure of abilities related to decisional capacity: differences among three standards for the MacCAT-CR in patients with schizophrenia. Schizophr Res (2006) 0.97
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry (2003) 0.96
Variability of judgments of capacity: experience of capacity evaluators in a study of research consent capacity. Psychosomatics (2011) 0.95
Consent for intravenous thrombolysis in acute stroke: review and future directions. Arch Neurol (2007) 0.95
First- and second-generation antipsychotics: learning from CUtLASS and CATIE. Arch Gen Psychiatry (2007) 0.94
How closely do institutional review boards follow the common rule? Acad Med (2012) 0.93
A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res (2012) 0.92
Treatment-related decision-making capacity in middle-aged and older patients with psychosis: a preliminary study using the MacCAT-T and HCAT. Am J Geriatr Psychiatry (2002) 0.91
First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs (2005) 0.91
Tarasoff and the researcher: does the duty to protect apply in the research setting? Am Psychol (1989) 0.91
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophr Res (2011) 0.91
Non-invasive brain stimulation in the detection of deception: scientific challenges and ethical consequences. Behav Sci Law (2009) 0.91
Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia. Schizophr Res (2011) 0.91